Future Science Group
Browse
FON-2022-0481 Infographic.pdf (2.92 MB)

BETA PRIME: Phase I study of AdAPT-001 as monotherapy and combined with a checkpoint inhibitor in superficially accessible, treatment-refractory solid tumors Infographic

Download (2.92 MB)
figure
posted on 2022-11-15, 15:42 authored by Santosh Kesari, Alberto Bessudo, Brian R Gastman, Anthony P Conley, Victoria M Villaflor, Lisle M Nabell, DeLisa Madere, Emma Chacon, Christina Spencer, Li Li, Christopher Larson, Tony Reid, Scott Caroen, Bryan Oronsky, Meaghan Stirn, Jeannie Williams, Minal A Barve

BETA PRIME: Phase I study of AdAPT-001 as

monotherapy and combined with a

checkpoint inhibitor in superficially

accessible, treatment-refractory solid tumors Infographic

Funding

EpicentRx, Inc. is the clinical trial sponsor. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

History

Usage metrics

    Future Oncology

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC